<DOC>
	<DOCNO>NCT02214602</DOCNO>
	<brief_summary>The aim study test value immediate post-operative intravesical instillation epirubicin patient intermediate high risk non muscle invasive bladder cancer ( NMIBC ) .</brief_summary>
	<brief_title>Value Immediate Post-operative Intravesical Epirubicin Intermediate &amp; High Risk Non Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description>Preoperative evaluation carry form routine laboratory investigation , abdominal pelvic US compute tomography ( CT ) magnetic resonance imaging ( MRI ) abdomen pelvis necessary . Then , patient subject complete TURBT . The patient transfer recovery room , careful monitoring patient carry 1st 30 min , confirm patient eligibility enrollment study exclusion case hematuria suspicious bladder perforation , patient enrol randomly one two group . The randomization process perform use computer-generated simple random table 1:1 ratio method close envelope . The 1st group receive intravesical instillation epirubicin -Placebo- ( control group ) , , 2nd group receive intravesical instillation epirubicin 50 mg 50 ml saline 0.9 % ( study group ) clamp urethral catheter 1 hour instillation period patient monitor local systemic adverse event ( acute abdomen , chill , fever , hot flush , abdominal rigidity , hematuria de-clamping catheter ) . Evaluation : Intraoperative early postoperative parameter interest record compare two group like EUA finding , tumor characteristic cystoscopy tumor size , site , shape , number , suspicion CIS , post instillation adverse event , cytology biopsy result . The patient discharge removal urethral catheter . They stratify either intermediate high risk histopathologically confirm NMIBC , follow outpatient clinic ( OPC ) receive adjuvant intravesical instillation chemotherapy immunotherapy accord European Association Urology ( EAU ) guideline risk group . The patient evaluate office cystoscopy urine cytology OPC 12 week , thereafter every 3 month first 2 year every 3 6 month accord risk category . During follow-up period , histopathologically confirm tumor classify recurrence . Time first recurrence primary end point study , length follow-up defined time inclusion last cystoscopy control . Methods evaluation follow-up : All patient evaluate entry follow-up interval . On study entry patient evaluate urinalysis , urine culture , serum creatinine , fast blood sugar level , complete blood count , chest X-ray , excretory urography ( IVU ) CT urography bladder wash cytology . CT contrast perform annually case high risk tumor category otherwise indicate . Complete TURBT visible tumor conduct patient stage grade determine accord 1987 stag classification World Health Organization ( WHO ) grade system 1973+ 2004 WHO grade system .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Ability give inform consent . Patients primary recurrent papillary Non muscle invasive bladder cancer ( NMIBC ) . Complete transurethral resection bladder tumor ( TURBT ) . Normal cardiac , hematological , renal function . Patients intermediate high risk NMIBC confirm histopathology . Inability give inform consent . Patients history previous radiotherapy systemic chemotherapy . Patients suffer immunodeficiency malignancy . Patients history hypersensitivity reaction epirubicin . Examination anesthesia ( EUA ) reveal palpable bladder mass . Patients primary , single , less 1cm papillary bladder tumor ( high likelihood low risk ) . Suspicion perforation bladder TURBT . Patients develop hematuria recovery room necessitate continuous bladder wash endoscopic haemostasis . Patients proven low risk NMIBC histopathology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>non muscle invasive bladder cancer</keyword>
	<keyword>intermediate high risk</keyword>
	<keyword>immediate single instillation</keyword>
	<keyword>Intravesical chemotherapy</keyword>
	<keyword>Disease prevention</keyword>
</DOC>